🔴 Telix Pharmaceuticals is trading 9.2% down today as potential share issuance raises dilution concerns

Telix Pharmaceuticals is trading 9.2% down at $11.31 after investors reacted negatively to the August 20 announcement of a potential at-the-market equity facility, raising dilution concerns despite strong half-year results.

• Reported US$477 million revenue, up 22% year over year, and adjusted EBITDA of US$52 million, up 146%.
• The ATM facility is discretionary, with no sales before an SEC prospectus supplement, but potential share issuance overshadowed the earnings beat.